Accueil   Diary - News   All news MaaT Pharma and Accinov

MaaT Pharma and Accinov

They sign a partnership agreement for the manufacture of investigational medicinal products

 

MaaT Pharma and Accinov have announced the signing of a partnership agreement for the creation of a GMP platform for the production of clinical batches for an investigational new drug to cure dysbiosis (imbalance of exchanges between the intestinal microbiome and the host) through  autologous micro-biotherapy, a solution which is currently totally unique. 

 

Accinov, the biomanufacturing centre which is part of the Lyonbiopôle biocluster, proposes services and hosting for biotech and pharmaceutical companies for the development of experimental products in compliance with GMP standards.  Within this partnership,  Accinov will take charge of the manufacturing of clinical batches of MaaT Pharma drug candidates in collaboration with its production and quality control teams, thus benefiting from a wide range of expertise and know-how concerning products and production processes.

 

MaaT Pharma has been hosted by Accinov in their premises since its creation at the beginning of 2015, and the two teams have been working together to implement GMP manufacturing activities within the biomanufacturing centre.

 

The autologous micro-biotherapy solution developed by MaaT Pharma will provide a safe, standardised treatment for hospital patients’ dysbiosis.  These imbalances in the intestinal microbiome, subsequent to certain major treatments, are notably known to result in the appearance of opportunistic infections or bacteria that are multi-resistant to antibiotics. 

Furthermore, they are the most frequent cause of diarrhoea following hospitalisation. 

 

The manufacturing platform installed by Accinov manages the whole range of activities connected to the investigational drug.  All different stages are mapped out, and particular care is devoted to safety measures.  The objective is to guarantee both the confidential nature and the total quality of individual patient medication.

At the end of 2015, Accinov obtained regulatory approval from the French authority ANSM for manufacture of the MaaT Pharma experimental drugs at its site. Using Accinov’s « plug & play »,

 

 


Read the press release

 

Logo MaâT 4e version

 

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree